Sp32

DEBATES ON GERD MANAGEMENT: PHARMACOLOGICS

Date
May 18, 2024

Presenter


Tracks

Related Products

Thumbnail for CLOSTRIDIOIDES DIFFICILE INFECTION INDUCES A PRO-STEATOTIC AND PRO-INFLAMMATORY METABOLIC STATE IN LIVER
CLOSTRIDIOIDES DIFFICILE INFECTION INDUCES A PRO-STEATOTIC AND PRO-INFLAMMATORY METABOLIC STATE IN LIVER
BACKGROUND: Recent studies suggest links between _Clostridioides difficile_ infection (CDI) and liver disorders, with non-alcoholic fatty liver disease (NAFLD) increasing CDI risk and CDI exacerbating the progression and prognosis of liver cirrhosis. Moreover, gut dysbiosis, often leading to _C…
Thumbnail for VONOPRAZAN FOR THE TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL
VONOPRAZAN FOR THE TREATMENT OF HEARTBURN IN NON-EROSIVE REFLUX DISEASE: A RANDOMIZED TRIAL
BACKGROUND: Proton pump inhibitors (PPIs) are the mainstay of therapy for non-erosive reflux disease (NERD). Potassium-competitive acid blockers (PCABs) have more potent and rapid inhibition of gastric acid secretion than PPIs…
Thumbnail for QUESTION AND ANSWER
QUESTION AND ANSWER
This session will provide an overview of the recent advances in diagnostic approaches to GERD, expansion in types and roles of diagnostic tools including ambulatory reflux monitoring, esophageal manometry, FLIP and MI in regards to GERD, and updates in guidelines and best practice advice…